The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting
Phase of Trial: Phase IV
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Corticosteroids
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms INTREPID
- Sponsors GlaxoSmithKline
- 01 Nov 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 29 Oct 2019 Status changed from active, no longer recruiting to completed.
- 07 Oct 2019 Planned End Date changed from 19 Sep 2019 to 8 Oct 2019.